{
  "denotations": [
    {
      "id": "T1",
      "obj": "Chemical",
      "span": {
        "begin": 15,
        "end": 24
      }
    },
    {
      "id": "T3",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 181,
        "end": 185
      }
    },
    {
      "id": "T5",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 225,
        "end": 229
      }
    },
    {
      "id": "T6",
      "obj": "Chemical",
      "span": {
        "begin": 45,
        "end": 56
      }
    },
    {
      "id": "T7",
      "obj": "Disease",
      "span": {
        "begin": 159,
        "end": 164
      }
    },
    {
      "id": "T8",
      "obj": "Chemical",
      "span": {
        "begin": 15,
        "end": 56
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "25695221_15",
  "text": "CONCLUSION : : Gefitinib in combination with bevacizumab as first-line therapy seems to be a favorable and well-tolerated treatment for patients with advanced NSCLC with activating EGFR gene mutations , especially those with EGFR exon 19 deletion mutations , although the primary end point was not met because the lower limit of the CI was less than 40 % ."
}
